# The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) ：Single-arm, Prospective, Open Clinical Study

> **NCT06125080** · PHASE2 · RECRUITING · sponsor: **Huihua Xiong** · enrollment: 78 (estimated)

## Conditions studied

- TNBC - Triple-Negative Breast Cancer

## Interventions

- **DRUG:** Utidelone
- **DRUG:** Tirelizumab
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT06125080
- **Lead sponsor:** Huihua Xiong
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-30
- **Primary completion:** 2025-10-30
- **Final completion:** 2026-10-30
- **Target enrollment:** 78 (ESTIMATED)
- **Last updated:** 2023-11-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06125080

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06125080, "The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) ：Single-arm, Prospective, Open Clinical Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06125080. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*